TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION

BACKGROUND: Brain metastases (BMs) are reported in 20–40% patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, has demonstrated an objective response rate (ORR) of 45% and median duration of response (mDOR) of 11.1 months, in METex14 skipping NSCLC patients in Cohort A...

Descripción completa

Detalles Bibliográficos
Autores principales: Bestvina, Christine M, Le, Xiuning, Veillon, Remi, Anderson, Ian, Patel, Jyoti, Demedts, Ingel, Garassino, Marina, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351173/
http://dx.doi.org/10.1093/noajnl/vdab071.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351173/
http://dx.doi.org/10.1093/noajnl/vdab071.021

Ejemplares similares